Open Access

Therapeutic potential of interleukin‑15 in cancer (Review)

  • Authors:
    • Gheorghița Isvoranu
    • Mihaela Surcel
    • Adriana Narcisa Munteanu
    • Ovidiu Gabriel Bratu
    • Florentina Ionita‑Radu
    • Monica Teodora Neagu
    • Marioara Chiritoiu‑Butnaru
  • View Affiliations

  • Published online on: April 24, 2021     https://doi.org/10.3892/etm.2021.10107
  • Article Number: 675
  • Copyright: © Isvoranu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The immune system is dysfunctional in cancer, and therapeutic approaches designated to restore immunity and increase long‑term overall survival are desirable. The role of immunotherapy is to trigger the immune system to recognize and destroy tumor cells. Interleukin‑15 (IL‑15) is a member of the common gamma‑chain (γc) cytokines that promote the differentiation and expansion of T cells, B cells and natural killer (NK) cells, leading to enhanced antitumor responses. This suggests that IL‑15 is a promising candidate for anticancer therapy. Renewed interest in cancer immunotherapy has led to an increased number of preclinical studies and clinical trials that have investigated the reliability and potency of IL‑15‑based agents, not only as single therapy, but also in combination with others. This review provides a description of these studies which show the advantages and disadvantages of IL‑15 as an immunotherapeutic agent. We present here the role of IL‑15 and pharmacologically improved IL‑15 superagonists as a single treatment or in combination with other therapeutic agents.
View References

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Isvoranu G, Surcel M, Munteanu AN, Bratu OG, Ionita‑Radu F, Neagu MT and Chiritoiu‑Butnaru M: Therapeutic potential of interleukin‑15 in cancer (Review). Exp Ther Med 22: 675, 2021
APA
Isvoranu, G., Surcel, M., Munteanu, A.N., Bratu, O.G., Ionita‑Radu, F., Neagu, M.T., & Chiritoiu‑Butnaru, M. (2021). Therapeutic potential of interleukin‑15 in cancer (Review). Experimental and Therapeutic Medicine, 22, 675. https://doi.org/10.3892/etm.2021.10107
MLA
Isvoranu, G., Surcel, M., Munteanu, A. N., Bratu, O. G., Ionita‑Radu, F., Neagu, M. T., Chiritoiu‑Butnaru, M."Therapeutic potential of interleukin‑15 in cancer (Review)". Experimental and Therapeutic Medicine 22.1 (2021): 675.
Chicago
Isvoranu, G., Surcel, M., Munteanu, A. N., Bratu, O. G., Ionita‑Radu, F., Neagu, M. T., Chiritoiu‑Butnaru, M."Therapeutic potential of interleukin‑15 in cancer (Review)". Experimental and Therapeutic Medicine 22, no. 1 (2021): 675. https://doi.org/10.3892/etm.2021.10107